Atrimer™ therapeutics in immunology: Braking a runaway immune system

Atrimer drug candidates hold promise in treating multiple autoimmune disorders, among them psoriasis, inflammatory bowel disease, and rheumatoid arthritis. The diversity of molecular design afforded by the Atrimer technology can produce drug candidates that intervene at various points of dysfunction along immunoregulatory pathways, either activating or blocking targets according to the therapeutic rationale. They may bind not only to trimeric targets identified in these pathways but also to dimeric, monomeric, and other protein targets.

©2010 Anaphore, Inc., All Rights Reserved.